

PRODUCT INFORMATION



XL184

Item No. 18464

CAS Registry No.: 849217-68-1

Formal Name: N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

Synonyms: BMS-907351, Cabozantinib

MF: C₂₈H₂₄FN₃O₅

FW: 501.5


Purity: ≥98%

UV/Vis.: λ_{max}: 242, 308, 322 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly



Laboratory Procedures

XL184 is supplied as a crystalline solid. A stock solution may be made by dissolving the XL184 in the solvent of choice. XL184 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of XL184 in these solvents is approximately 2, 4, and 3 mg/ml, respectively.

XL184 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, XL184 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. XL184 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

XL184 is a pan tyrosine kinase inhibitor that primarily targets VEGFR2 (IC₅₀ = 0.035 nM) and c-Met (IC₅₀ = 1.3 nM) but also inhibits RET, c-Kit, Axl, FLT3, and Tie2 (IC₅₀s = 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively).¹ In *in vivo* breast, lung, and glioma tumor models that represent dysregulated c-Met and VEGFR signaling, XL184 was shown to reduce tumor and endothelial cell proliferation, inhibiting both angiogenesis and metastasis.¹ XL184 has undergone clinical trial in a broad number of cancers, including thyroid carcinoma, prostate cancer, ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma, and glioblastoma.²

References

1. Yakes, F.M., Chen, J., Tan, J., *et al.* Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Mol. Cancer Ther.* **10(12)**, 2298-2308 (2011).
2. Zhang, Y., Guessous, F., Kofman, A., *et al.* XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. *IDrugs.* **13(2)**, 112-121 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/25/2015

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM